Filing Details
- Accession Number:
- 0000950170-24-027509
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-06 20:13:26
- Reporting Period:
- 2024-03-04
- Accepted Time:
- 2024-03-06 20:13:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779308 | Catriona Yale | C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080 | Chief Development Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-04 | 10,000 | $6.36 | 88,415 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-03-04 | 10,646 | $21.09 | 99,061 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-04 | 20,646 | $35.49 | 78,415 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-04 | 10,000 | $0.00 | 10,000 | $6.36 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-04 | 10,646 | $0.00 | 10,646 | $21.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,172 | 2029-01-15 | No | 4 | M | Direct | |
| 74,354 | 2029-12-12 | No | 4 | M | Direct |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 23, 2023, previously adopted by the Reporting Person.
- Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
- The options are vested and currently exercisable.
Billionaire Hedge Funds
